ALL PRODUCTS ARE INTENDED AS RESEARCH CHEMICALS AND ARE NOT LABELED FOR HUMAN USE.
Karabakhtsian R, Broude N, Shalts N, Kochlatyi S, Goodman R, Henderson AS
The study found the peptide well-tolerated with minimal toxicity risk, though adverse events were described as mild to moderate
PMID: 34380875
GHK-Cu significantly reduced inflammatory cytokines TNF-alpha, IL-6, and IL-1beta, enhanced mucosal repair, and upregulated tight junction protein expression through inhibition of the SIRT1/STAT3 signaling pathway
[1] [9] The trial enrolled 387 adults (BMI 27 kg/m, without diabetes) and randomly assigned them 1:1:1:1:1 to once-weekly subcutaneous survodutide at 0.6, 2.4, 3.6, or 4.8 mg or placebo, with a 20-week dose-escalation period followed by 26 weeks of maintenance, for 46 weeks total